Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Solabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 20/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Solabegron SCHEMBL29410896 | 1.00 | ADRB3 (0.98) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29410905 | 1.00 | ADRB3 (0.98) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL2890305 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL2596555 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL2596558 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29357347 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL29386981 | 0.99 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Solabegron SCHEMBL15269302 | 0.97 | ADRB3 (0.96) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4585906 | 0.93 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4585914 | 0.93 | ADRB3 (0.85) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366016-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LTD (GB) | 2010-08-25 | — | — | EP | claimed |
| US-7425639-B2 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | claimed |
| EP-1235788-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLAMINE DERIVATIVES HAVING AN ANTI-OBESITY AND ANTI-DIABETIC PROPERTIES | GLAXO GROUP LTD (GB) | 2005-03-30 | — | — | EP | claimed |
| US-20040077868-A1 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | B3AR THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| US-8642661-B2 | Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists | ALTHERX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120035118-A1 | PHARMACEUTICAL COMBINATIONS | ALTHERX, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1366016-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| US-7709677-B2 | e.g.3-{3-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]phenyl}isonicotinic acid ; useful as agonists at atypical beta-adrenoceptors; treatment of hyperglycaemia, animal growth promoters, blood platelet aggregation inhibitors, as positive inotropic agents and antiatherosclerotic agent | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080306278-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-7425639-B2 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1235788-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLAMINE DERIVATIVES HAVING AN ANTI-OBESITY AND ANTI-DIABETIC PROPERTIES | GLAXO GROUP LTD (GB) | 2005-03-30 | — | — | EP | disclosed |
| US-20040077868-A1 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | B3AR THERAPEUTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1366016-A2 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6548523-B2 | Such as (R)-5-(3-((2-((2-(3-chlorophenyl)-2-hydroxyethyl) amino)ethyl)amino)phenyl)-3-pyridinecarboxylic acid; one pot process | SMITHKLINE BEECHAM CORPORATION | 2003-04-15 | — | — | US | disclosed |
| US-20020198220-A1 | Such as (R)-5-(3-((2-((2-(3-chlorophenyl)-2-hydroxyethyl) amino)ethyl)amino)phenyl)-3-pyridinecarboxylic acid; one pot process | B3AR THERAPEUTICS, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002066418-A2 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077868-A1 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
| US-20020198220-A1 | Such as (R)-5-(3-((2-((2-(3-chlorophenyl)-2-hydroxyethyl) amino)ethyl)amino)phenyl)-3-pyridinecarboxylic acid; one pot process | CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2A6 | ADRB3 689/4885ADRB1 637/4885ADRB2 652/4885 |
| US-20080306278-A1 | PROCESS | ADRB3, ADRA1D, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 4/4885 |
| US-20120035118-A1 | PHARMACEUTICAL COMBINATIONS | ADRB3, ADRB2, ADRA2B | ADRB3 1/4885ADRB1 4/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.